Admedus Ltd
ABN 35 088 221 078
REGISTERED OFFICE:
26 Harris Road Malaga Western Australia 6090
ASX RELEASE
ADMEDUS TO HOST SHAREHOLDER WEBINART +61 (0)8 9266 0100
F +61 (0)8 9266 0199
E info.au@admedus.com
www.admedus.com
Admedus shareholder webinar Tuesday, 28 February 2017
12pm AEDT Sydney/Melbourne; 11am AEST Brisbane; 9am AWST Perth
Brisbane, Australia 16 February 2017
Admedus (ASX:AHZ) today announced that it will hold a shareholder webinar on Tuesday, 28 February 2017 to discuss the outcome of the Company's restructure to date and half yearly results.
The webinar will be presented by the Company's Chairman and Interim CEO, Mr. Wayne Paterson, and will address Admedus' business progress and performance.
The webinar will be live and shareholders are welcome to submit questions in the lead up to the webinar to: info@admedus.com
Webinar details: Date: Tuesday, 28 February 2017 Time: 12pm AEDT Sydney/Melbourne; 11am AEST Brisbane; 9am AWST Perth Please register to attend the seminar at:https://attendee.gotowebinar.com/register/4459538179101828354
Once you have registered to attend the webinar via the link above, you will receive a confirmation email with the webcast link and dial-in details.
Follow us:Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com
For more information, please contact:Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Signal Leadership Communication Inc. Mr Bob Pickard
Tel: +1 (647) 822 1000
bob.pickard@signaleadership.com
Media EuropeFTI Consulting
Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000
admedus@fticonsulting.com
US InvestorRx Communications Group, LLC Melody A. Carey
+1 917 322 2571
mcarey@rxir.com
About Admedus LimitedAdmedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
Admedus Ltd. published this content on 16 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 February 2017 21:56:11 UTC.
Original documenthttp://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6810218
Public permalinkhttp://www.publicnow.com/view/9E9379450B05F1D8449CA272791682F88EF42A1D